PHARM Pharming Group N.V.

Price Chart

Executive Summary

Pharming Group N.V. announced a positive opinion from the EMA's CHMP recommending marketing authorization for Joenja® (leniolisib) as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in the European Union. The final decision from the European Commission is expected in Q2 2026, which would allow commercialization across all EU member states, Iceland, Liechtenstein, and Norway. This follows recent approval in Japan and builds on existing approvals in the U.S., U.K., Australia, and Israel.

Actionable Insight

Key Facts

• CHMP of the EMA issued a positive opinion for Joenja® (leniolisib) for the treatment of APDS in patients aged 12+.
• Final European Commission decision expected within ~2 months (Q2 2026).
• If approved, Joenja will be the first authorized treatment for APDS in the EU.
• Approval based on Phase II/III trial of 31 patients showing statistically significant improvement in immune dysregulation and immunodeficiency.
• Long-term safety data from 37 patients treated for a median of 3 years was also submitted.
• Joenja is already approved in the U.S., U.K., Australia, Israel, and Japan (age 4+).
• Leniolisib is under regulatory review in Canada and other countries.
• APDS affects ~1–2 per million people globally; current diagnostic delay averages 7 years.

Financial Impact

Potential multi-hundred-million dollar revenue opportunity across EU and EEA based on orphan drug pricing and unmet need, though no specific financial guidance provided.

Risk Factors

• European Commission could theoretically reject the CHMP opinion, though this is rare.
• Commercial uptake may be limited by low disease awareness and diagnostic delays.
• Long-term safety or real-world effectiveness could emerge as concerns despite positive trial data.

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status